Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Method for restraining aspergillus fumigates-pseudomonas aeruginosa mixed biological film

A Pseudomonas aeruginosa and biofilm technology, applied in the field of microorganisms, can solve the problems of obvious liver and kidney damage, many side effects, and increased mortality, and achieve the effects of reducing the economic burden of patients, low extraction cost, and abundant raw materials

Inactive Publication Date: 2019-05-10
GUANGXI MEDICAL UNIVERSITY
View PDF2 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

It has reference value for current clinical medication. The clinical effect of mixed infection of Aspergillus fumigatus and Pseudomonas aeruginosa is not good. Common antifungal drugs have obvious liver and kidney damage and many side effects.
It is easy to cause the disease to persist and increase the death rate

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for restraining aspergillus fumigates-pseudomonas aeruginosa mixed biological film
  • Method for restraining aspergillus fumigates-pseudomonas aeruginosa mixed biological film

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0019] A method for inhibiting Aspergillus fumigatus-Pseudomonas aeruginosa mixed biofilm, the method uses isochlorogenic acid to inhibit the formation of biofilm.

[0020] Further, the concentration of the above-mentioned isochlorogenic acid is 2000-1000 μg / mL.

[0021] Further, the concentration of the above-mentioned isochlorogenic acid is 1000 μg / mL.

[0022] Further, the above-mentioned isochlorogenic acid is used in combination with voriconazole and ceftazidime, and the inhibitory effect is better.

[0023] Further, the concentration ranges of voriconazole and ceftazidime are 1-4 μg / mL and 16-64 μg / mL, respectively.

[0024] Further, the concentration of voriconazole is 1 μg / mL, and the concentration of ceftazidime is 16 μg / mL.

Embodiment 2

[0025] Embodiment 2: verify the validity of this method

[0026] The verification method includes the following steps:

[0027] (1) Drug preparation: take 20mg isochlorogenic acid A (IRC) and dissolve it with 1ml 100% dimethyl sulfoxide, and prepare a solution with a concentration of 20000 μg / ml; take 4 mg voriconazole (VRC) and dissolve it with 1ml 100% dimethyl sulfoxide Dissolve sulfoxide and prepare a solution with a concentration of 4000 μg / ml; take 6.4 mg of ceftazidime (CAZ) and dissolve it with 1 ml of 100% dimethyl sulfoxide to prepare a solution with a concentration of 6400 μg / ml; Store at 20℃~-25℃;

[0028] (2) Establishment of static mixed biofilm model in vitro:

[0029] a. Preparation of Aspergillus fumigatus spore suspension. The tested Aspergillus fumigatus strain was inoculated into potato dextrose agar (PDA) slant medium, recovered at 37°C for 72 hours, then transferred to another PDA slant medium for 37°C activation for 72h, and 8 mL containing Wash the P...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Concentrationaaaaaaaaaa
Concentrationaaaaaaaaaa
Concentrationaaaaaaaaaa
Login to View More

Abstract

The invention discloses a method for restraining an aspergillus fumigates-pseudomonas aeruginosa mixed biological film. According to the method, isochlorogenic acid is utilized for restraining formingof the mixed biological film. According to the method, the application dosage of antibiotic can be effectively reduced, and the aspergillus fumigates-pseudomonas aeruginosa mixed biological film canbe effectively restrained. The medical cost is expected to be reduced, and pain of a patient is expected to be relieved. By means of the experimental method, it is clear that isochlorogenic acid combined antifungal and antibacterial drugs have an obvious restraining effect on the mixed biological film formed by aspergillus fumigates-pseudomonas aeruginosa, and the restraining effect is obviously larger than the effect generated when pure antifungal drugs and antibacterial drug are combined for use.

Description

technical field [0001] The invention relates to a method for inhibiting the production of fungal biofilm, which belongs to the technical field of microorganisms. Background technique [0002] Studies on many infectious diseases in humans have shown that pathogenic bacteria exist in the human body mainly in the form of biofilms. Current research shows that biofilms are far more pathogenic to humans than planktonic bacteria. Domestic and foreign studies have shown that antibiotics The dose required for the inhibition of biofilm is 30-2000 times that of the inhibition of planktonic bacteria. Studies have shown that Pseudomonas aeruginosa is the most common type of long-term colonization in the lungs of COPD patients with pulmonary infection and cystic fibrosis, and Pseudomonas aeruginosa mixed with Aspergillus fumigatus is the most common type of mixed infection , the two often exist in the lungs of patients in the form of mixed biofilms, so the anti-inflammatory treatment is ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/216A61K31/506A61K31/546A61P31/04
Inventor 李更森孔晋亮罗劲卜文博王可谢杰鹏刘冬梅
Owner GUANGXI MEDICAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com